Federal Medical Marijuana Rescheduling Lawsuit Advancing

Federal Medical Marijuana Rescheduling Lawsuit Advancing

Advocates prepare for October 16 hearing in D.C.

WASHINGTON, DC — A decade after the Coalition for Rescheduling Cannabis (CRC) filed its petition seeking to have marijuana moved from Schedule I of the Controlled Substances Act, the federal courts will finally review the scientific evidence regarding the therapeutic efficacy of marijuana. The DC Circuit Court of Appeals announced late last week that it will hear oral arguments in October in a lawsuit filed by Americans for Safe Access (ASA) to force the government to act.

The lawsuit, Americans for Safe Access vs. DEA, was filed in January after the DEA denied the CRC’s rescheduling petition the previous July. The DEA took nine years to decide to do nothing about rescheduling marijuana.

Under the Controlled Substances Act, Schedule I is reserved for drugs that “have a high potential for abuse, have no currently accepted medical use in treatment in the United States, and there is a lack of accepted safety for use of the drug or other substance under medical supervision.”

Patient advocates charge the DEA and other federal agencies have ignored an increasing mountain of evidence on marijuana’s therapeutic efficacy and that marijuana is “currently accepted [for] medical use in treatment” in 17 states and the District of Columbia. They also charge that the rescheduling process for marijuana has been “encumbered by politics” and that federal agencies are throwing roadblocks in the way of scientific research on medical marijuana.

“Medical marijuana patients are finally getting their day in court,” said ASA chief counsel Joe Elford. “This is a rare opportunity for patients to confront politically motivated decision-making with scientific evidence of marijuana’s medical efficacy. What’s at stake in this case is nothing less than our country’s scientific integrity and the imminent needs of millions of patients.”

Oral arguments will take place Tuesday, October 16, at 9:30am at the E. Barrett Prettyman US Courthouse in downtown Washington.

  • Markgamble0924

    If the President wants this next Election then he needs to get this reschedule. Sick and Dying folks are running out of time …Stroke of a Pen.

  • http://www.facebook.com/people/Adam-William-Majkowski/1507188872 Adam William Majkowski

    The evidence is clear. We have found ourselves in the same exact situation as when Timothy Leary fought and legalized it for us in the 60’s. The current scheduling law contradicts itself. The evidence is overwhelming that it does in fact have medical uses and is not in any way dangerous. This is not the definition of a schedule one substance. We should be including LSD and magic mushrooms in this discussion as well to remove those from schedule one as well. They are not dangerous or addicting. Cocaine, crack and heroine belong on the schedule one if they can be proven to have no medical value whicjh I doubt that can be proven. The entire drug schedule is incorrect at best and surely detrimental to our country.

  • Johnny oneye

    At this point the federal government looks silly . Other countries have bypassed the prohibition of drugs , especially testing cannabis and the endocannabinoid system we are born with .
    End the war on weed , i support Americans for safe access.

  • Bre

    Juicing Marijuana is non-psychoactive and incredibly medicinal with minimal side-effects. Probably the best herb on the planet and it should be legal for every citizen to grow it in their yards for juicing.

  • http://twitter.com/revraygreen revraygreen

    In Iowa, 2/17/10, the Board of Pharmacy ruled to remove cannabis from schedule I, for since 1979 in Iowa it has been in dual classification(Schedule I& II) per research U of I..

    http://youtu.be/9szOHy3vRPw Another in the IOWA NICER series of videos being put together to raise awareness to the informal, insufferable crazy fool lawmakers running the hen house in Des Moines Iowa……

  • Pingback: Southern Research Institute Names Arthur J. Tipton, Ph.D. President and CEO()